Trial · NCT05791708
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patterns of CAD and CAS disease characteristics | Up to 6 years | CAD or CAS characteristics at diagnosis, enrollment, and during follow up (e.g., criteria used for diagnosis, symptoms, laboratory results) will be described. |
| Primary | Number of participants with CAD or CAS complications | Up to 6 years | Thromboembolic events (venous, arterial or cerebral), deaths related to CAD or CAS, other CAD/CAS complications (e.g., acute hemolytic crisis, hemolysis-related complications), and other comorbid conditions occurring before enrollment, at enrollment, and during follow up will be described. |
| Primary | Patterns of use of CAD and CAS treatments | Up to 6 years | CAD or CAS treatments received before enrollment, at enrollment, and during the follow up period will be summarized. CAD or CAS symptoms and complications, autoimmune disorders or lymphoproliferative disorders, physician assessment of treatment status, and changes in laboratory results will be described by CAD or CAS treatments. |
| Primary | Number of participants with health-resource utilization | Up to 6 years | Health resource utilization may include hospitalizations (including length of stay), outpatient visits, emergency room visits, specific transfusion visits, nursing home/rehabilitation center stays, and home healthcare visits during registry follow-up period |
| Primary | Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ) | Up to 6 years | |
| Primary | Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) | Up to 6 years | |
| Primary | 36-Item Short Form Survey Instrument (SF-36) v2 | Up to 6 years | |
| Primary | Sutimlimab cohort: Sutimlimab treatment patterns | Up to 6 years | Sutimlimab dosing information, reasons for dose adjustments, reasons for discontinuation will be described. |
| Primary | Sutimlimab cohort: Number of participants with adverse events, serious adverse events, adverse events of special interests (AESIs), other events of interests (e.g., Treatment emergent) | Up to 6 years | |
| Primary | Sutimlimab cohort: change from baseline in hemoglobin | From baseline up to 6 years | |
| Primary | Sutimlimab cohort: change from baseline in bilirubin | From baseline up to 6 years | |
| Primary | Sutimlimab cohort: change from baseline in Lactate dehydrogenase (LDH) | From baseline up to 6 years | |
| Primary | Sutimlimab cohort: number of blood cells transfusions | Up to 6 years |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05791708/registered